Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B

At least four classes of structurally distinct natural products with potent antiproliferative activities target the translation elongation factor eEF1A1, which is best known as the G-protein that delivers amino acyl transfer RNAs (aa-tRNAs) to ribosomes during mRNA translation. We present molecular models in atomic detail that provide a common structural basis for the high-affinity binding of didemnin B, ternatin, ansatrienin B and nannocystin A to eEF1A1, as well as a rationale based on molecular dynamics results that accounts for the deleterious effect of replacing alanine 399 with valine. The proposed binding site, at the interface between domains I and III, is eminently hydrophobic and exists only in the GTP-bound conformation. Drug binding at this site is expected to disrupt neither loading of aa-tRNAs nor GTP hydrolysis but would give rise to stabilization of this particular conformational state, in consonance with reported experimental findings. The experimental solution of the three-dimensional structure of mammalian eEF1A1 has proved elusive so far and the highly homologous eEF1A2 from rabbit muscle has been crystallized and solved only as a homodimer in a GDP-bound conformation. Interestingly, in this dimeric structure the large interdomain cavity where the drugs studied are proposed to bind is occupied by a mostly hydrophobic α-helix from domain I of the same monomer. Since binding of this α-helix and any of these drugs to domain III of eEF1A(1/2) is, therefore, mutually exclusive and involves two distinct protein conformations, one intriguing possibility that emerges from our study is that the potent antiproliferative effect of these natural products may arise not only from inhibition of protein synthesis, which is the current dogma, but also from interference with some other non-canonical functions. From this standpoint, this type of drugs could be considered antagonists of eEF1A1/2 oligomerization, a hypothesis that opens up novel areas of research.

[1]  Nathan T. Ross,et al.  Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex , 2015, eLife.

[2]  E. Nishida,et al.  Microtubule severing by elongation factor 1 alpha. , 1994, Science.

[3]  Jonathan M Lee,et al.  Binding of Elongation Factor eEF1A2 to Phosphatidylinositol 4-Kinase β Stimulates Lipid Kinase Activity and Phosphatidylinositol 4-Phosphate Generation* , 2007, Journal of Biological Chemistry.

[4]  H. Kakeya,et al.  The asymmetric total synthesis of (+)-cytotrienin a, an ansamycin-type anticancer drug. , 2008, Angewandte Chemie.

[5]  F. J. Luque,et al.  Dynamic undocking and the quasi-bound state as tools for drug discovery , 2016, Nature Chemistry.

[6]  Gerhard Klebe,et al.  Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands. , 2016, Journal of medicinal chemistry.

[7]  Michiko Iitsuka,et al.  BPOZ‐2 directly binds to eEF1A1 to promote eEF1A1 ubiquitylation and degradation and prevent translation , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[8]  M. Schlaak,et al.  Sensitization of tumor cells to ribotoxic stress-induced apoptotic cell death: a new therapeutic strategy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  B. Clark,et al.  The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein. , 1998, Nucleic acids research.

[10]  T. Kinzy,et al.  eEF1A: Thinking Outside the Ribosome* , 2010, The Journal of Biological Chemistry.

[11]  J. Taunton,et al.  Decoding Mammalian Ribosome-mRNA States by Translational GTPase Complexes , 2016, Cell.

[12]  A. Vertegaal,et al.  Mapping the SUMOylated landscape , 2015, The FEBS journal.

[13]  R. Hilgenfeld,et al.  Crystal structure of active elongation factor Tu reveals major domain rearrangements , 1993, Nature.

[14]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[15]  T. Kataoka,et al.  Cytotrienin A, a translation inhibitor that induces ectodomain shedding of TNF receptor 1 via activation of ERK and p38 MAP kinase. , 2011, European journal of pharmacology.

[16]  F. J. Luque,et al.  Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. , 2011, Journal of the American Chemical Society.

[17]  Jason C. Cole,et al.  WebCSD: the online portal to the Cambridge Structural Database , 2010, Journal of applied crystallography.

[18]  D. Williams,et al.  An enthalpic component in cooperativity: the relationship between enthalpy, entropy, and noncovalent structure in weak associations. , 2001, Journal of the American Chemical Society.

[19]  Kai Liu,et al.  Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations , 2017, Journal of Computer-Aided Molecular Design.

[20]  T. Lefebvre,et al.  O-GlcNAcylation: A New Cancer Hallmark? , 2013, Front. Endocrinol..

[21]  F. Gago,et al.  Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. , 2004, Journal of medicinal chemistry.

[22]  H. Kakeya,et al.  Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer drug-induced apoptosis. , 1998, Cancer research.

[23]  M. Watabe,et al.  Activation of MST/Krs and c-Jun N-terminal Kinases by Different Signaling Pathways during Cytotrienin A-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[24]  J. Pelletier,et al.  Inhibition of translation by cytotrienin A--a member of the ansamycin family. , 2010, RNA.

[25]  Paul D. Adams,et al.  Molecular Dynamics Applied to X‐Ray Structure Refinement , 2002 .

[26]  K. Ando,et al.  Tetrahymena eukaryotic translation elongation factor 1A (eEF1A) bundles filamentous actin through dimer formation. , 2006, Journal of biochemistry.

[27]  D. Uemura,et al.  Whole structure-activity relationships of the fat-accumulation inhibitor (-)-ternatin: recognition of the importance of each amino acid residue. , 2008, Journal of medicinal chemistry.

[28]  P. Toogood,et al.  Inhibition of protein synthesis by didemnin B: how EF-1alpha mediates inhibition of translocation. , 2000, Biochemistry.

[29]  M. Haga,et al.  Eukaryotic Translation Elongation Factor 1A Induces Anoikis by Triggering Cell Detachment* , 2012, The Journal of Biological Chemistry.

[30]  D. Case,et al.  Revised AMBER parameters for bioorganic phosphates. , 2012, Journal of chemical theory and computation.

[31]  V. Pletnev,et al.  Molecular structures of two crystalline forms of the cyclic heptapeptide antibiotic ternatin, cyclo[-beta-OH-D-Leu-D-Ile-(NMe)Ala-(NMe)Leu-Leu-(NMe)Ala-D-(NMe)Ala-]. , 2009, International journal of peptide and protein research.

[32]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[33]  D. Porteous,et al.  Structural Models of Human eEF1A1 and eEF1A2 Reveal Two Distinct Surface Clusters of Sequence Variation and Potential Differences in Phosphorylation , 2009, PloS one.

[34]  A. El'skaya,et al.  Mammalian translation elongation factor eEF1A2: X-ray structure and new features of GDP/GTP exchange mechanism in higher eukaryotes , 2014, Nucleic acids research.

[35]  M. Wiedmann,et al.  Interaction of the Eukaryotic Elongation Factor 1A with Newly Synthesized Polypeptides* , 2002, The Journal of Biological Chemistry.

[36]  Gautam R Desiraju,et al.  Hydrogen bridges in crystal engineering: interactions without borders. , 2002, Accounts of chemical research.

[37]  Chen-feng Qi,et al.  Eef1a2 Promotes Cell Growth, Inhibits Apoptosis and Activates JAK/STAT and AKT Signaling in Mouse Plasmacytomas , 2010, PloS one.

[38]  H. Matter,et al.  Discovery, Structure Elucidation, and Biological Characterization of Nannocystin A, a Macrocyclic Myxobacterial Metabolite with Potent Antiproliferative Properties. , 2015, Angewandte Chemie.

[39]  Duncan Poole,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. , 2013, Journal of chemical theory and computation.

[40]  Nathan T. Ross,et al.  Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties. , 2015, Angewandte Chemie.

[41]  D. Uemura,et al.  (−)-Ternatin, a highly N-methylated cyclic heptapeptide that inhibits fat accumulation: structure and synthesis , 2006 .

[42]  G. Sheldrick,et al.  Crystal and molecular structure of didemnin A, an antiviral depsipeptide. , 2009, International journal of peptide & protein research.

[43]  O. Numata,et al.  Roles of Three Domains of Tetrahymena eEF1A in Bundling F-actin , 2008, Zoological science.

[44]  A. Chambery,et al.  Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics. , 2011, Biochimie.

[45]  F. Gago,et al.  MM-ISMSA: An Ultrafast and Accurate Scoring Function for Protein-Protein Docking. , 2012, Journal of chemical theory and computation.

[46]  S. Kuentzel,et al.  Biochemical and cellular effects of didemnins A and B. , 1984, Cancer research.

[47]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[48]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[49]  P. Arcari,et al.  New insights on the interaction between the isoforms 1 and 2 of human translation elongation factor 1A. , 2015, Biochimie.

[50]  P. Schirmacher,et al.  EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR‐dependent stabilization of MDM4 in hepatocellular carcinoma , 2014, Hepatology.

[51]  S. Luengo,et al.  Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product. , 2003, Journal of medicinal chemistry.

[52]  Huajun Zheng,et al.  Bacterial biosynthesis and maturation of the didemnin anti-cancer agents. , 2012, Journal of the American Chemical Society.

[53]  Faye L. Cruickshank,et al.  Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues. , 2014, Biochemical and biophysical research communications.

[54]  T. Kataoka Translation inhibitors and their unique biological properties. , 2012, European journal of pharmacology.

[55]  F. Gago,et al.  Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin , 2016, Scientific Reports.

[56]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[57]  R. G. Hughes,et al.  Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate. , 1981, Science.

[58]  Lars J Jensen,et al.  Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation , 2017, Nature Structural &Molecular Biology.

[59]  C. Csortos,et al.  Elongation factor-1A1 is a novel substrate of the protein phosphatase 1-TIMAP complex. , 2015, The international journal of biochemistry & cell biology.

[60]  J. Gray,et al.  Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer , 2002, Nature Genetics.

[61]  S. Schreiber,et al.  GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. , 1994, The Journal of biological chemistry.

[62]  A. Ortiz,et al.  A new implicit solvent model for protein–ligand docking , 2007, Proteins.

[63]  H. Newbery,et al.  Translation Elongation Factor eEF1A2 Is Essential for Post-weaning Survival in Mice* , 2007, Journal of Biological Chemistry.

[64]  R. Singer,et al.  The translation elongation factor eEF1A1 couples transcription to translation during heat shock response , 2014, eLife.

[65]  Q. Kang,et al.  Biosynthesis of 3,5-AHBA-derived natural products. , 2012, Natural product reports.

[66]  A. Ciechanover,et al.  Protein synthesis elongation factor EF-1 alpha is essential for ubiquitin-dependent degradation of certain N alpha-acetylated proteins and may be substituted for by the bacterial elongation factor EF-Tu. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Poul Nissen,et al.  Elongation factors in protein biosynthesis. , 2003, Trends in biochemical sciences.

[68]  Dudley H. Williams,et al.  Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes. , 2004, Angewandte Chemie.

[69]  J. Côté,et al.  eEF1A is a novel component of the mammalian nuclear protein export machinery. , 2008, Molecular biology of the cell.